Navigation Links
ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohn's Disease at the Digestive Disease Week (DDW) 2010 Conference
Date:5/4/2010

CCX282-B is a small molecule, orally bioavailable drug that is administered in capsule form and which is believed to modify the inappropriate immune system response underlying inflammatory bowel disease (IBD) by blocking the CCR9 chemokine receptor. In adults, CCR9 is a highly specific receptor expressed by inflammatory T cells that migrate to the digestive tract. The migration of inflammatory cells to the small and large intestine is believed to cause the persistent inflammation seen in Crohn's disease and ulcerative colitis -- the two principal forms of IBD. In addition to the recently completed PROTECT-1 study, ChemoCentryx has completed six Phase I clinical trials and one four-week Phase II Crohn's disease trial of CCX282-B at doses up to 1000 mg twice daily, demonstrating that the drug candidate is well-tolerated and appropriate for once-daily or twice-daily oral dosing. CCX282-B may offer advantages over existing therapeutic approaches for Crohn's disease by potentially offering reduced side effects and convenient oral dosing to patients. Traficet-EN is now being developed under a strategic alliance with GlaxoSmithKline's Center of Excellence for External Drug Discovery (CEEDD).  In January 2010, GlaxoSmithKline (GSK) exercised an option to obtain an exclusive worldwide license for the further development and commercialization of Traficet-EN.

About Crohn's Disease

Crohn's disease is a chronic inflammatory condition of the gastrointestinal tract. It is estimated that the disease affects over 500,000 patients in Europe and North America. Patients suffer periods of flare-ups characterized by intense symptoms, interspersed with periods of relative remission where symptoms decrease or disappear. As Crohn's disease is a chronic condition, patients continue on therapy from t
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
2. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
3. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
4. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
5. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
6. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
7. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. Spherix Reports Second Quarter Earnings
10. Tapestry Reports Second Quarter 2007 Results
11. Callisto Reports on Second-Quarter 2007 Milestones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... YORK , Sept. 3, 2015 This ... used to save millions of lives across globe. This ... Kingdom of Saudi Arabia . Stakeholders ... material suppliers, government agencies and regulatory bodies. The ... studied from two perspectives: by products and by end ...
(Date:9/3/2015)... Calif. , Sept. 3, 2015 Nevro ... company that is providing innovative evidence-based solutions for the ... will be presenting at the Morgan Stanley Global Healthcare ... City.  Nevro management is scheduled to ... accessible via a live audio webcast, accessible in the ...
(Date:9/3/2015)... 2015  Ascendis Pharma A/S (Nasdaq: ... that applies its innovative TransCon technology to ... plans to present at several upcoming investor ... in BostonDate: , Thursday, September 10, 2015 Time: ... Merrill Lynch Global Healthcare Conference in LondonDate: ...
Breaking Medicine Technology:Saudi Arabia Defibrillators Market: & Advanced Life Support Defibrillators; End Users; Industry Analysis, Size, Volume, Growth, Trends and Forecast 2014 - 2020 2Ascendis Pharma A/S to Present at Three Upcoming Investor Conferences 2
... LOS ANGELES , July 13 Medical Tactile, Inc. ... Medical Technologies, Inc., based in Victoria , Canada , has ... the exclusive Sales & Marketing rights for SureTouch™ , the non-invasive ... , , , ...
... New England Biolabs (NEB) has expanded its line ... Quick DNA Sample Prep Reagent Set 2 and Master Mix ... GS FLX Titanium™ and GS Junior™ instruments. These new products ... library preparation. The Master Mix Set further streamlines the workflow, ...
Cached Medicine Technology:Partnership Brings Breast Image Documentation Technology to Women Around the World 2New England Biolabs Launches NEBNext™ Quick DNA Sample Prep Reagent Sets for Use With Roche/454 Next Generation Sequencing Platforms 2
(Date:9/4/2015)... ... September 04, 2015 , ... Many consumers are looking for a quick and convenient way ... , The patent-pending K Med Cups provide a quick and simple way to brew a ... cold, flu or cough. As a result, they enhance comfort and health. The invention features ...
(Date:9/4/2015)... , ... September 04, 2015 , ... Having access to ... has led to an increasing amount of unnecessary emergency room visits which affects hospitals’ ... taxes the country’s health bill. Fortunately, a solution to alleviate this problem has recently ...
(Date:9/4/2015)... ... 04, 2015 , ... Compliance officers deal with many high-risk ... physician self-referral law. “Stark Law DOs and DON’Ts: Best Practices for Your ... (AIS), will detail which deals are attracting the most government scrutiny and what ...
(Date:9/4/2015)... ... September 04, 2015 , ... Friday night, Chicago lovebirds Jenny ... Rescue’s A Night of Hope event supporting families affected by autism, raising nearly $250,000. ... Joe Salas, joined together at the Oscar Swan Inn to support the cause. ...
(Date:9/3/2015)... ... September 03, 2015 , ... TransPack Toon gives users a set of 90 ... and framing transitions in 30 different styles. Presets range from snow, underwater, forest, futuristic, ... , TransPack Toon features 90 cartoon transitions from 30 unique styles. Editors can ...
Breaking Medicine News(10 mins):Health News:Redesigned Packaging for Powdered Medicinal Mix Invented by InventHelp® Client (CBA-2637) 2Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 2Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 3Health News:Sept. 17 Webinar to Offer Best Practices for Physician Contracts 2Health News:Jenny McCarthy & Donnie Wahlberg Help Raise Over $200,000 For Generation Rescue’s ‘Night Of Hope’ Chicago Charity Event 2Health News:Pixel Film Studios Releases TransPack Toon, a New FCPX Transition 2
... to a couple of pegs when it comes to alcohol ... are capable of scaling down// the risks of a brain ... Indraprastha Apollo Hospital’s senior consultant Harsh Rastogi. ,"Drinking ... the more alcohol one consumes, the greater the risk of ...
... day by day and the mortality rate is also directly proportional ... the increasing number of AIDS/HIV patients// United Nations Development Program HIV/AIDS ... was started under the Global Fund for AIDS in Liberia. ... raise in the number of people affected by AIDS/HIV in the ...
... the US chief of AIDS research has revealed that the ... he is convinced that there is a lack of incentive ... of Health’s AIDS Research Chief made this announcement at an ... fetch profits, if the vaccine really works. ,Strong ...
... A research was conducted by the American Researchers Richard Ivry ... He said that left side of the brain // can ... same colour. This is due to the fact that the ... ,Researchers to study this feature of the brain ...
... genes such as microRNAs (miRNAs) belong to the newly ... of North Carolina have discovered two genes // belonging ... attributed to the proper development of muscles in the ... (1993) in the genome of the worms. The genes ...
... in United Kingdom which allows prescription of nicotine patches ... women as the risk associated with smoking is higher ... earlier the sale of nicotine patches was not allowed ... with chronic diseases such as heart, liver and kidney ...
Cached Medicine News:Health News:Colour Identification Lies Wholly On the Left Hemisphere of the Brain. 2Health News:Genetic mystery behind muscle development unraveled. 2
The ultra micro tip for the new Eppendorf 2000/2100 series ultra micro pipettors provides accurate drawing and dispensing everytime....
... Sterilized Diamond Tips are available as ... Tips are irradiated by gamma-rays for more ... certificate of sterilization, specifying the date of ... usepractical, no need to autoclave. SterilPack Diamond ...
This ultra micro tip for the Eppendorf and Nichiryo/BenchMate 0.5-10 L pipettors is perfect for working with low volume....
1000 L, Bulk Recommended for 500 and 1000 L pipettes....
Medicine Products: